Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients

Archives of Internal Medicine

Volumn 167, Issue 8, 2007, Pages 840-846

  Fischer, Michael A ^a   Morris, Charles A ^a   Winkelmayer, Wolfgang C ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON STORAGE; IRON THERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; DRUG UTILIZATION REVIEW; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATOCRIT; HUMANS; INPATIENTS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 34247499065     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.8.840     Document Type: Article

References (26)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175-1178.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-78.
3. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
4. Rizzo JD, Lichtin AE, Woolf SH, et al; American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303-2320.
5. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med. 1992;117:739-748.
6. Faris PM, Ritter MA, Abels RI; American Erythropoietin Study Group. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am. 1996;78:62-72.
7. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
8. Cassels C. CHOIR silenced as findings show increased risk of CVD outcomes/death. http://www.medscape.com/viewarticle/539039. Accessed October 6, 2006.
9. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet. 2003;362:1255-1260.
10. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.
11. Pollack A. Drug company halts trials of Procrit. New York Times. November 27, 2003.
12. Rowland C. As kidney drug doses rise, so do warnings. Boston Globe. September 14, 2006; §A1.
13. Kimmel PL, Greer JW, Milam RA, Thamer M. Trends in erythropoietin therapy in the U.S. dialysis population: 1995-1998. Semin Nephrol. 2000;20:335-344.
14. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
15. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
16. Corwin HL, Gettinger A, Pearl RG, et al; EPO Critical Care Trial Group. Efficacy of recombinant human erythropoietin in critcally ill patients: a randomized controlled trial. JAMA. 2002;288:2827-2835.
17. Sunder-Plassman G, Horl W. Iron therapy during erythropoietin treatment in haemodialysis patients. Kidney Forum. 2000;2:23-25.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis. 2001;37(suppl 1):S182-S238.
19. Goodnough L. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy. Nephrol Dial Transplant. 2002;17:14-18.
20. Kaltwasser JP, Gottschalk R. Erythropoietin and iron. Kidney Int Suppl. 1999;55:S49-S56.
21. Macdougall IC, Horl WH, Jacobs C, et al. European best practice guidelines 6-8: assessing and optimizing iron stores. Nephrol Dial Transplant. 2000;15:20-32.
22. Tonelli M, Winkelmayer W, Jindal K, Owen W, Manns B. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64:295-304.
23. Besarab A, Bolton W, Browne J, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
24. Weiss G. Iron and anemia of chronic disease. Kidney Int Suppl. 1999;55:S12-S17.
25. US Renal Data System. USRDS 1996 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1996.
26. Eckardt KU; Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) Trial. The CREATE Trial: building the evidence. Nephrol Dial Transplant. 2001;16(suppl 2):16-18.